Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers. Issue 5 (13th February 2019)
- Record Type:
- Journal Article
- Title:
- Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers. Issue 5 (13th February 2019)
- Main Title:
- Lesinurad: Evaluation of Pharmacokinetic and Pharmacodynamic Interactions With Warfarin in Healthy Volunteers
- Authors:
- Shen, Zancong
Lee, Caroline A.
Wallach, Kathleen
Valdez, Shakti
Wilson, David M.
Kerr, Bradley
Gillen, Michael - Abstract:
- Abstract: Lesinurad is a selective uric acid reabsorption inhibitor approved for use in combination with xanthine oxidase inhibitors for the treatment of hyperuricemia associated with gout. In vitro, lesinurad was shown to be a weak inhibitor of cytochrome P450 (CYP)2C9 and a weak inducer of CYP3A4. Warfarin is a widely prescribed oral coumarin‐based anticoagulant commonly prescribed in gout patients. In an open‐label clinical study in healthy adult male subjects, the effects of multiple daily doses of 400 mg lesinurad on the pharmacokinetics and pharmacodynamics of a single dose of 25 mg warfarin (racemic mixture of R‐ and S‐ enantiomers) were evaluated. Lesinurad had no effect on the absorption or the exposure (area under the concentration‐time curve [AUC] and peak concentration) of the more active S‐warfarin enantiomer. A slight reduction (19%) in overall plasma exposure (AUC) was observed for the R‐warfarin enantiomer. Lesinurad had no meaningful clinical impact on anticoagulation activity as measured by prothrombin time, activated partial thromboplastin time, and international normalized ratio of prothrombin time and Factor VII clotting activity. Overall, the administration of warfarin in the presence of multiple‐dose lesinurad was devoid of clinically significant drug‐drug interaction.
- Is Part Of:
- Clinical pharmacology in drug development. Volume 8:Issue 5(2019)
- Journal:
- Clinical pharmacology in drug development
- Issue:
- Volume 8:Issue 5(2019)
- Issue Display:
- Volume 8, Issue 5 (2019)
- Year:
- 2019
- Volume:
- 8
- Issue:
- 5
- Issue Sort Value:
- 2019-0008-0005-0000
- Page Start:
- 657
- Page End:
- 663
- Publication Date:
- 2019-02-13
- Subjects:
- CYP2C9 -- gout -- lesinurad -- pharmacodynamics -- pharmacokinetics -- serum urate -- URAT1 -- warfarin
Drugs -- Testing -- Periodicals
Drug development -- Periodicals
Clinical pharmacology -- Periodicals
615.580724 - Journal URLs:
- http://cpd.sagepub.com ↗
http://onlinelibrary.wiley.com/journal/10.1002/%28ISSN%292160-7648 ↗
http://accp1.onlinelibrary.wiley.com/hub/journal/10.1002/(ISSN)2160-7648/ ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1002/cpdd.662 ↗
- Languages:
- English
- ISSNs:
- 2160-7648
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.330300
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 11004.xml